The facility in Shiga will include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials
Catalent has expanded the services and capabilities at its facility in Shiga, Japan to include the storage, kitting, and distribution of advanced therapies at ultra-low temperatures for clinical trials.
State-of-the-art cryogenic freezers alongside material transfer equipment have been installed that are designed to retain the integrity of investigational advanced therapy products by minimising their time-out-of-environment.
The expansion forms part of Catalent’s ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinical supply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialised, ultra-low temperature storage capabilities.
The 6000 sqm Shiga site opened in October 2021 to support customers both locally and globally, providing flexible clinical supply solutions, including primary packaging, Catalent’s FastChain® demand-led supply, white glove handling and logistics.
This investment allows us to provide the optimum logistical solution for every customer’s individual needs
“The market in Japan for advanced therapies and new modalities continues to grow, along with the demand for companies such as Catalent that have the advanced infrastructure to handle the supply and distribution of these highly sensitive products, as well as the specialised expertise and comprehensive knowledge to manage these supply chains,” commented Tadahiro Matsumura, Catalent’s President of Japan.
He added: “This investment allows us to provide the optimum logistical solution for every customer’s individual needs, and the foundation to increase capacity as requirements change and grow.”
With sites in the US, UK, Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent’s clinical supply services meet a broad range of international compliance and distribution requirements to support global clinical trials.